drugset / Trial / NCT06323824
Office-based Methadone Versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment.
Phase 4
Recruiting
600 enrolled
Yale University
Alameda Health System · collabBoston Medical Center (BMC) · collabHennepin Healthcare Research Institute · collabKaiser Permanente · collabMarshall Health · collabNational Institute on Drug Abuse (NIDA) · collabNational Institutes of Health (NIH) · collabThe Emmes Company, LLC · collabUniversity of California, San Francisco · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this clinical trial is to compare the effectiveness of office-based methadone with pharmacy administration and/or dispensing to office-based buprenorphine for the treatment of opioid use disorder. This study will also examine factors influencing the implementation of office-based methadone.
Timeline
- Start
- 2024-06-04
- Primary completion
- 2028-12
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Buprenorphine | Other / unclassified | 225 ug | — |
| Comparator | Buprenorphine | Other / unclassified | 8 mg | — |
| Comparator | Buprenorphine | Other / unclassified | 16 mg | — |
| Comparator | Buprenorphine | Other / unclassified | 24 mg | — |
| Comparator | Buprenorphine | Other / unclassified | 32 mg | — |
| Comparator | Buprenorphine | Other / unclassified | 64 mg | — |
| Comparator | Buprenorphine | Other / unclassified | 96 mg | — |
| Comparator | Buprenorphine | Other / unclassified | 100 mg | — |
| Comparator | Buprenorphine | Other / unclassified | 128 mg | — |
| Comparator | Buprenorphine | Other / unclassified | 300 mg | — |
| Subject | Methadone | Other / unclassified | 10 mg | Oral |
| Subject | Methadone | Other / unclassified | 50 mg | Oral |